JP7748377B2 - 抗ａｘｌ抗体及び組成物 - Google Patents

抗ａｘｌ抗体及び組成物

Info

Publication number
JP7748377B2
JP7748377B2 JP2022551247A JP2022551247A JP7748377B2 JP 7748377 B2 JP7748377 B2 JP 7748377B2 JP 2022551247 A JP2022551247 A JP 2022551247A JP 2022551247 A JP2022551247 A JP 2022551247A JP 7748377 B2 JP7748377 B2 JP 7748377B2
Authority
JP
Japan
Prior art keywords
antibody
seq
axl
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022551247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515821A5 (https=
JPWO2021171257A5 (https=
JP2023515821A (ja
Inventor
ジェッティング，トーベン
リンドステット，トリーネ
ウィラー，アントン
ウォルソー，アンネ
メランデル，エヴァ・マリア・カールセン
ヤコブセン，ヤヌス・スコウ
ハンセン，ランディ・ウェスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of JP2023515821A publication Critical patent/JP2023515821A/ja
Publication of JP2023515821A5 publication Critical patent/JP2023515821A5/ja
Publication of JPWO2021171257A5 publication Critical patent/JPWO2021171257A5/ja
Application granted granted Critical
Publication of JP7748377B2 publication Critical patent/JP7748377B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022551247A 2020-02-28 2021-02-26 抗ａｘｌ抗体及び組成物 Active JP7748377B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982852P 2020-02-28 2020-02-28
US62/982,852 2020-02-28
PCT/IB2021/051636 WO2021171257A1 (en) 2020-02-28 2021-02-26 Anti-axl antibodies and compositions

Publications (4)

Publication Number Publication Date
JP2023515821A JP2023515821A (ja) 2023-04-14
JP2023515821A5 JP2023515821A5 (https=) 2024-03-01
JPWO2021171257A5 JPWO2021171257A5 (https=) 2024-03-01
JP7748377B2 true JP7748377B2 (ja) 2025-10-02

Family

ID=75426640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551247A Active JP7748377B2 (ja) 2020-02-28 2021-02-26 抗ａｘｌ抗体及び組成物

Country Status (17)

Country Link
US (1) US11807688B2 (https=)
EP (1) EP4110824A1 (https=)
JP (1) JP7748377B2 (https=)
KR (1) KR20220148237A (https=)
CN (1) CN115210263A (https=)
AR (1) AR121441A1 (https=)
AU (1) AU2021225490B2 (https=)
BR (1) BR112022015977A2 (https=)
CA (1) CA3170975A1 (https=)
CL (1) CL2022002259A1 (https=)
CO (1) CO2022012159A2 (https=)
IL (1) IL295596A (https=)
MX (1) MX2022010670A (https=)
MY (1) MY209381A (https=)
PE (1) PE20221783A1 (https=)
PH (1) PH12022552041A1 (https=)
WO (1) WO2021171257A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026001894A1 (zh) * 2024-06-24 2026-01-02 上海医药集团生物治疗技术有限公司 靶向axl的嵌合抗原受体及其用途
CN119591720B (zh) * 2024-11-28 2026-02-10 北京大学深圳研究生院 抗人axl抗体、基因及其应用
CN119912586B (zh) * 2024-12-31 2025-09-30 四川省肿瘤医院 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063965A1 (ja) 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Anexelektoに結合するモノクローナル抗体、およびその利用
JP2013538553A (ja) 2010-06-18 2013-10-17 ジェネンテック， インコーポレイテッド 抗ａｘｌ抗体及び使用方法
JP2018525354A (ja) 2015-07-10 2018-09-06 ゲンマブ エー／エス 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
JP2019519199A (ja) 2016-04-12 2019-07-11 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｔｉｍ−３抗体および組成物
WO2019197506A1 (en) 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment
JP2019528677A (ja) 2016-06-22 2019-10-17 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
BRPI1013428A2 (pt) * 2009-05-11 2019-07-02 U3 Pharma Gmbh anticorpos humanizados para axl
MX2015005757A (es) * 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
JP6931609B2 (ja) 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
PL3368572T3 (pl) * 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063965A1 (ja) 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Anexelektoに結合するモノクローナル抗体、およびその利用
JP2013538553A (ja) 2010-06-18 2013-10-17 ジェネンテック， インコーポレイテッド 抗ａｘｌ抗体及び使用方法
JP2018525354A (ja) 2015-07-10 2018-09-06 ゲンマブ エー／エス 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
JP2019519199A (ja) 2016-04-12 2019-07-11 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｔｉｍ−３抗体および組成物
JP2019528677A (ja) 2016-06-22 2019-10-17 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
WO2019197506A1 (en) 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment

Also Published As

Publication number Publication date
PH12022552041A1 (en) 2023-11-29
BR112022015977A2 (pt) 2022-10-11
PE20221783A1 (es) 2022-11-16
WO2021171257A1 (en) 2021-09-02
CN115210263A (zh) 2022-10-18
EP4110824A1 (en) 2023-01-04
MX2022010670A (es) 2022-09-23
KR20220148237A (ko) 2022-11-04
AR121441A1 (es) 2022-06-08
IL295596A (en) 2022-10-01
AU2021225490B2 (en) 2025-11-27
CA3170975A1 (en) 2021-09-02
US11807688B2 (en) 2023-11-07
CL2022002259A1 (es) 2023-04-14
TW202146455A (zh) 2021-12-16
JP2023515821A (ja) 2023-04-14
CO2022012159A2 (es) 2022-10-31
AU2021225490A1 (en) 2022-09-15
US20210269532A1 (en) 2021-09-02
MY209381A (en) 2025-07-04

Similar Documents

Publication Publication Date Title
JP7662617B2 (ja) 抗ｃｄ７３抗体
IL258214B2 (en) Antibodies - anti pd-1 and preparations
JP7679399B2 (ja) 抗ｆｌｔ３抗体及び組成物
JP7748377B2 (ja) 抗ａｘｌ抗体及び組成物
JP2024520577A (ja) 抗ｎｋｇ２ａ抗体及び組成物
US20210214454A1 (en) Anti-cd40 antibodies and compositions
JP2025526279A (ja) 抗ＴＮＦα抗体および組成物
RU2837590C9 (ru) Антитела против axl и композиции
RU2837590C1 (ru) Антитела против axl и композиции
TWI920062B (zh) 抗axl抗體及組合物
RU2836004C1 (ru) Антитела и композиции против flt3
HK40081002A (en) Anti-axl antibodies and compositions
CA3000564C (en) Anti-pd-1 antibodies and compositions
EA052808B1 (ru) Антитела и композиции против flt3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250919

R150 Certificate of patent or registration of utility model

Ref document number: 7748377

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350